Results 191 to 200 of about 642,036 (246)
Some of the next articles are maybe not open access.
Superactive Gonadotropin-Releasing Hormone Agonists
Annual Review of Medicine, 1983Superactive GnRH agonists represent a new class of pharmacologic agents that inhibit reproductive function in both men and women when administered chronically. These hormonal drugs are being tested extensively as both male and female contraceptive agents, as a treatment for prostate cancer, and as a new treatment for idiopathic precocious puberty ...
R S, Swerdloff, D, Heber
openaire +2 more sources
Gonadotropin-Releasing Hormone Agonists for Endometriosis
New England Journal of Medicine, 2008A 36-year-old woman with a presumptive diagnosis of endometriosis presents with long-standing pelvic pain that is not relieved by means of oral contraceptives or medroxyprogesterone. Treatment with a gonadotropin-releasing hormone agonist is recommended.
openaire +3 more sources
Conversion of a gonadotropin-releasing hormone antagonist to an agonist
Nature, 1982Gonadotropin-releasing hormone (pyroGlu1-His2-Trp3-Ser4-Tyr5-Gly6-Leu7-Arg8-Pro9-Gly10 amide, GnRH) stimulates pituitary luteinizing hormone (LH) release. An antagonist, D-pyroGlu1-D-Phe2-D-Trp3-D-Lys6-GnRH (GnRH-Ant), binds to the pituitary GnRH receptor and inhibits GnRH-stimulated (10−9 M) gonadotropin release from pituitary cultures (IC50 = 2 × 10 ...
P M, Conn +4 more
openaire +2 more sources
Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin
Fertility and Sterility, 1989Fifty-one women with pelvic endometriosis were treated with the gonadotropin-releasing hormone agonist (GnRHa) Buserelin (Hoechst Holland N.V., Amsterdam, The Netherlands) 300 micrograms three times a day intranasally for 6 months. Forty-nine women completed treatment; 42 were available for 6 months of follow-up following treatment.
FRANSSEN, AMHW +4 more
openaire +3 more sources
Treatment of Hirsutism with a Gonadotropin-Releasing Hormone Agonist (Nafarelin)∗
The Journal of Clinical Endocrinology & Metabolism, 1986GnRH analogs inhibit the secretion of gonadotropins and, therefore, that of estrogens and androgens of ovarian origin. The purpose of this study was to investigate the use of one superactive agonistic GnRH analog, nafarelin, in the treatment of hirsutism. Six hirsute women were treated with nafarelin (1 000 micrograms/day) for 6 months.
J L, Andreyko, S E, Monroe, R B, Jaffe
openaire +2 more sources
Gonadotropin-releasing hormone agonists
Current Opinion in Obstetrics and Gynecology, 1991GnRH agonist (GnRHa) medications are now routinely used by gynecologists, urologists, medical endocrinologists, and pediatric endocrinologists alike. GnRHa are frequently highly effective in diminishing pain derived from endometriotic lesions. Current US Food and Drug Administration approval limits GnRHa regimens to a 6-month course largely because of ...
openaire +2 more sources
Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists
American Journal of Obstetrics and Gynecology, 1999Our purpose was to assess the changes in uterine volume and uterine artery pulsatility index in response to gonadotropin-releasing hormone agonist treatment in women undergoing hysterectomy for nonfibroid-related uterine bleeding.A double-blind, placebo-controlled randomized trial of 51 women awaiting hysterectomy in a gynecology outpatient clinic was ...
A D, Weeks, S R, Duffy, J J, Walker
openaire +2 more sources
The effects of a gonadotropin-releasing hormone agonist on testicular histology
Fertility and Sterility, 1987We have described the histologic changes in the testes of men treated with buserelin for prostatic cancer. If these changes are reversible, then the agonist analogues, together with testosterone replacement therapy, could be used safely for male contraception.
J, Waxman +4 more
openaire +2 more sources
Gonadotropin-releasing hormone agonists
Postgraduate Medicine, 1994Use of gonadotropin-releasing hormone (GnRH) agonists produces a transient increase and subsequent long-term reduction in concentrations of pituitary hormones, resulting in gonadal hormone suppression. This reversible suppression is useful in treating diseases dependent on these hormones.
openaire +2 more sources
Treatment of Prostate Cancer with Gonadotropin-Releasing Hormone Agonists
Endocrine Reviews, 1986It is now well established that chronic treatment with GnRH agonists offers an advantageous alternative to orchiectomy and estrogens for the treatment of prostate cancer. Castration levels of androgens can thus be easily achieved without side effects other than those related to castration levels of serum androgens.
F, Labrie +7 more
openaire +2 more sources